Small Molecules
27 August 2019
InDex Pharmaceuticals Meets Primary Endpoint in the Phase IIb Study CONDUCT with Cobitolimod in Ulcerative Colitis27 August 2019
LEO Pharma Files IND Application to FDA for a Clinical Study of JW1601/LP0190 in the US23 August 2019
Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China23 August 2019
Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN22 August 2019
Roxadustat approved in China for the treatment of anaemia in non-dialysis-dependent patients with chronic kidney disease20 August 2019
Outlook Therapeutics Completes Patient Enrollment for NORSE 1 a Phase 3 Clinical Trial for ONS-5010 in Wet AMD20 August 2019
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure20 August 2019
Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)20 August 2019
Forendo Pharma Commences Phase 1b Proof of Mechanism Study with its Lead Endometriosis Program, HSD17B1 Inhibitor FOR-621919 August 2019
Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD17 August 2019
U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With MyelofibrosisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports